Patient, industry, and regulatory perspective on antibody‐drug conjugates dose optimization

Antibody-drug conjugates (ADCs) represent a rapidly evolving area of oncology drug development.A critical gap remains regarding how we can widen ADC therapeutic windows that prevents patients from receiving more effective treatments for their life-threatening illnesses.To maximize the safety and efficacy of next-generation ADCs, it is imperative to optimize the dosages by integrating the totality of evidence, including patient perspectives via quantitative modeling.Here, we summarize the patient, industry, and regulatory perspectives on ADC dose optimization.